{"doi":"10.17615/ryrv-wq75","title":"Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19","abstract":"BACKGROUND: Development of safe and effective SARS-CoV-2 therapeutics is a high priority. Amubarvimab and romlusevimab are noncompeting anti-SARS-CoV-2 monoclonal antibodies with an extended half-life. OBJECTIVE: To assess the safety and efficacy of amubarvimab plus romlusevimab. DESIGN: Randomized, placebo-controlled, phase 2 and 3 platform trial. (ClinicalTrials.gov: NCT04518410). SETTING: Nonhospitalized patients with COVID-19 in the United States, Brazil, South Africa, Mexico, Argentina, and the Philippines. PATIENTS: Adults within 10 days onset of symptomatic SARS-CoV-2 infection who are at high risk for clinical progression. INTERVENTION: Combination of monoclonal antibodies amubarvimab plus romlusevimab or placebo. MEASUREMENTS: Nasopharyngeal and anterior nasal swabs for SARS-CoV-2, COVID-19 symptoms, safety, and progression to hospitalization or death. RESULTS: Eight-hundred and seven participants who initiated the study intervention were included in the phase 3 analysis. Median age was 49 years (quartiles, 39 to 58); 51% were female, 18% were Black, and 50% were Hispanic or Latino. Median time from symptom onset at study entry was 6 days (quartiles, 4 to 7). Hospitalizations and/or death occurred in 9 (2.3%) participants in the amubarvimab plus romlusevimab group compared with 44 (10.7%) in the placebo group, with an estimated 79% reduction in events (<em>P</em>&nbsp;&lt;&nbsp;0.001). This reduction was similar between participants with 5 or less and more than 5 days of symptoms at study entry. Grade 3 or higher treatment-emergent adverse events through day 28 were seen less frequently among participants randomly assigned to amubarvimab plus romlusevimab (7.3%) than placebo (16.1%) (<em>P</em>&nbsp;&lt;&nbsp;0.001), with no severe infusion reactions or drug-related serious adverse events. LIMITATION: The study population was mostly unvaccinated against COVID-19 and enrolled before the spread of Omicron variants and subvariants. CONCLUSION: Amubarvimab plus romlusevimab was safe and significantly reduced the risk for hospitalization and/or death among nonhospitalized adults with mild to moderate SARS-CoV-2 infection at high risk for progression to severe disease. PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases of the National Institutes of Health.","journal":"UNC Libraries","year":2025,"id":561553,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.962,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":962389,"name":"Yan Li","orcid":"0000-0002-1567-9365","position":1,"is_corresponding":false},{"id":108340,"name":"Jonathan Z. Li","orcid":"0000-0001-9914-9662","position":2,"is_corresponding":false},{"id":74899,"name":"Rachel Bender Ignacio","orcid":"0000-0001-6167-1447","position":3,"is_corresponding":false},{"id":315361,"name":"Kara W Chew","orcid":"0000-0003-4865-4348","position":4,"is_corresponding":false},{"id":1043611,"name":"Bharat Mocherla","orcid":null,"position":5,"is_corresponding":false},{"id":1042981,"name":"Qing Zhu","orcid":"0000-0001-5148-5157","position":6,"is_corresponding":false},{"id":340150,"name":"David A. Wohl","orcid":"0000-0002-7764-0212","position":7,"is_corresponding":false},{"id":1006550,"name":"ACTIV- A Study Team","orcid":null,"position":8,"is_corresponding":false},{"id":1043609,"name":"Ulises D’Andrea Nores","orcid":null,"position":9,"is_corresponding":false},{"id":385130,"name":"Justin Ritz","orcid":"0000-0001-6307-4849","position":10,"is_corresponding":false},{"id":396976,"name":"Judith S. Currier","orcid":"0000-0003-4279-4737","position":11,"is_corresponding":false},{"id":419481,"name":"Carlee Moser","orcid":"0000-0001-5601-9112","position":12,"is_corresponding":false},{"id":218333,"name":"Manish C. Choudhary","orcid":"0000-0002-3192-7840","position":13,"is_corresponding":false},{"id":105520,"name":"David M. Margolis","orcid":"0000-0001-5714-0002","position":14,"is_corresponding":false},{"id":65752,"name":"Michael D. Hughes","orcid":"0000-0001-8562-2316","position":15,"is_corresponding":false},{"id":474421,"name":"Mauricio Pinilla","orcid":null,"position":16,"is_corresponding":false},{"id":1042983,"name":"Lijie Zhong","orcid":"0000-0001-7070-2225","position":17,"is_corresponding":false},{"id":259563,"name":"Courtney V. Fletcher","orcid":"0000-0002-3703-7849","position":18,"is_corresponding":false},{"id":1043610,"name":"Keila Hoover","orcid":null,"position":19,"is_corresponding":false},{"id":806068,"name":"Arzhang Cyrus Javan","orcid":null,"position":20,"is_corresponding":false},{"id":351140,"name":"Eric S. Daar","orcid":"0000-0003-1880-7331","position":21,"is_corresponding":false},{"id":806067,"name":"Rinki Deo","orcid":null,"position":22,"is_corresponding":false},{"id":1463559,"name":"Ji Ma","orcid":"0000-0002-4228-6620","position":23,"is_corresponding":false},{"id":36878,"name":"Davey M. Smith","orcid":"0000-0003-3603-1733","position":24,"is_corresponding":false},{"id":109932,"name":"William A. Fischer","orcid":"0000-0002-4900-098X","position":25,"is_corresponding":false},{"id":571854,"name":"Teresa H. Evering","orcid":null,"position":26,"is_corresponding":false},{"id":387866,"name":"Mark J Giganti","orcid":"0000-0003-2255-9756","position":27,"is_corresponding":false},{"id":249713,"name":"Joseph J. Eron","orcid":"0000-0002-4938-0644","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:55:58.259104Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}